Oxaliplatin-induced interstitial lung disease

Asia-Pacific Journal of Clinical Oncology

Volumn 4, Issue 3, 2008, Pages 175-180

  Piccolo, Francesco ^a   Feeney, Kynan T ^b   Tribe, Anthony E ^a,d   Thompson, Phil J ^a,c,d   Millward, Michael J ^b,c   Van Hazel, Guy A ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Lung Institute of Western Australia   (Australia)

Author keywords

Drug reaction; Interstitial lung disease; Oxaliplatin; Pneumonitis

Indexed keywords

AMIODARONE; CAPECITABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; GLICLAZIDE; HYDROCORTISONE; METFORMIN; OXALIPLATIN; OXYGEN; PREDNISOLONE; WARFARIN;

ABDOMINAL CRAMP; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CASE REPORT; COLON CARCINOMA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EMPHYSEMA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; OXYGEN SATURATION; PRIORITY JOURNAL; SPIROMETRY; STOMATITIS; SYMPTOM; TACHYPNEA; THORAX RADIOGRAPHY;

EID: 51349098973     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2008.00187.x     Document Type: Article

References (14)

1. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-51.
2. Andre T, Bensmaine MA, Louvet C et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-8.
3. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
4. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
5. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
6. Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006; 33: 98-105.
7. Trisolini R, Lazzari Agli L, Tassinari D etal. Acute lung injury associated with 5-fluorouracil and oxaliplatin combined chemotherapy. Eur Respir J 2001; 18: 243-5.
8. Gagnadoux F, Roiron C, Carrie E, Monnier-Cholley L, Lebeau B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 2002; 25: 388-90.
9. Jung KH, Kil SY, Choi IK et al. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Int J Tuberc Lung Dis 2006; 10: 1181-2.
10. Ruiz-Casado A, Garcia MD, Racionero MA. Pulmonary toxicity of 5-fluorouracil and oxaliplatin. Clin Transl Oncol 2006; 8: 624.
11. Yague XH, Soy E, Merino BQ, Puig J, Fabregat MB, Colomer R. Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol 2005; 7: 515-17.
12. Pasetto LM, Monfardini S. Is acute dyspnea related to oxaliplatin administration? World J Gastroenterol 2006; 12: 5907-8.
13. Garrido M, O'Brien A, Gonzalez S, Clavero JM, Orellana E. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: Case report. Chest 2007; 132: 1997-9.
14. Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: A report of three cases. Respir Med 2008; 102: 273-9.